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ABSTRACT: None of the available osteoporosis therapies have been shown to completely abolish the risk of
fractures. In clinical practice, the outcome may be even poorer. In 880 patients prescribed with antiresorptives
(alendronate, risedronate, and raloxifene) for >1 year, a fragility fracture was recorded in 8.9%/year of them.
This incidence is considerably higher than that observed in randomized clinical trials, and it was significantly
related to poor compliance and lack of supplementation with calcium and vitamin D.
Introduction: Osteoporotic fracture is one of the most important public health concerns among the elderly.
Currently available therapies have been shown to significantly decrease the risk of fracture, although none of
them completely abolishes this risk. In clinical practice, poor treatment response may also result from a
number of other factors.
Materials and Methods: The Incidence and ChAracterization of inadequate clinical Responders in Osteopo-
rosis (ICARO) is a multicenter, observational study carried out in Italy. It aimed to analyze, in postmeno-
pausal women with established osteoporosis, the risk factors for an “inadequate clinical response” to drug
therapy, defined as the occurrence of new vertebral or nonvertebral fragility fractures in patients prescribed,
for at least 1 year, alendronate, risedronate, or raloxifene, with a compliance >50%.
Results: In 880 patients treated with antiresorptive agents for a median of 2.0 years (95% CI: 1.0–4.5) years,
the “inadequate clinical responder (ICR)” subjects over the observation period were 220 (25%), with an
annual incidence of 8.9%. ICRs, compared with “adequate clinical responders (ACRs),” had more pretreat-
ment fractures and were treated longer (2.8 versus 1.8 years; p < 0.001). After multiple adjustment for these
confounding factors, significant determinants of inadequate clinical response were a poorer treatment com-
pliance and a less frequent co-administration of calcium and vitamin D supplements.
Conclusions: The incidence of fractures during treatment with antiresorptive agents in a clinical setting is
considerably higher than that observed in randomized clinical trials. Inadequate compliance to treatment and
lack of supplementation of calcium and vitamin D are major determinants of this poor response.
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INTRODUCTION
OSTEOPOROTIC FRACTURES REMAIN a major public healthproblem, causing substantial morbidity and mortal-
ity.(1,2) The primary aims of therapeutic intervention in os-
teoporosis are to prevent the first fragility fracture and to
avoid subsequent fractures in those patients who already
sustained a fracture. There is strong evidence from random-
ized controlled trials (RCTs) for the efficacy of currently
available therapies in reducing the risk of fracture in pa-
tients with osteoporosis.(3) However, none of the currently
available medications completely abolish the risk of frac-
ture, and clinical trials have shown that a significant pro-
portion of patients with existing fractures will sustain new
fractures in a relatively short period while on treat-
ment.(4–10)
To date, there is no consensus on what constitutes non-
response or an inadequate clinical response to therapy in
the individual patient. Changes in BMD have been used in
clinical practice as a surrogate marker of response to osteo-
porosis drug therapy, and definitions of inadequate re-
sponse based on BMD have been proposed.(11) However,
changes in BMD vary considerably between individuals,
and there is only a weak correlation between changes in
BMD and fracture rate.(12,13)
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The occurrence of a fragility fracture while on therapy is
a key indicator of poor response to treatment, although its
predictive power remains questionable because pharmaco-
logical treatment never abolishes the fracture risk in indi-
vidual patients. The relative risk (RR) reduction of sustain-
ing new fractures while on therapy is ∼50% for most RCTs.
However, fracture incidence in the active treatment arms of
the pivotal osteoporosis drug trials may fluctuate from
2.1% to 18.1% over 3–5 years according to the severity of
the disease.(4–9,14) Poor treatment response may result from
a number of other factors,(11) usually controlled in RCTs
but frequently encountered in daily clinical practice.
Observational studies examine outcomes of treatment in
clinical practice and are useful for determining how out-
comes vary with patient characteristics and environment.
The Incidence and Characterization of inadequate clinical
Responders in Osteoporosis (ICARO) is the first study de-
signed to analyze, in postmenopausal women with estab-
lished osteoporosis and in a naturalistic setting, the risk
factors for an inadequate clinical response to osteoporosis
drug therapy, defined as the occurrence of a new fragility
fracture while on treatment.
MATERIALS AND METHODS
Study design
ICARO is a multicenter, observational study carried out
in 55 centers for the management of osteoporosis, evenly
distributed over the Italian territory. The main aim of the
study is the evaluation of incidence and risk factors for
inadequate clinical response in osteoporotic patients pre-
scribed with antiresorptive drugs (alendronate, risedronate,
raloxifene) for at least 1 year. The “inadequate clinical re-
sponse” (ICR) as opposed to “adequate clinical response”
(ACR) is defined as the occurrence of X-rays evident of
new vertebral or nonvertebral fragility fractures at least 6
months after initiation of the antiresorptive therapy.
Recruitment started in November 2002 and was com-
pleted in November 2003. The study was submitted to local
ethics committees according with the Italian legislation as
an “observational study” (i.e., the patients were not asked
to undergo any type of examinations exceeding those rou-
tinely performed in each center). All patients gave in-
formed consent for the provision and collection of data
regarding care and outcomes for a period of at least 1 year.
Investigators were asked to screen for study entry consecu-
tive postmenopausal women referred to the center for a
scheduled visit. Here we report the results of the retrospec-
tive phase of the study. A prospective phase of the same
cohort of patients is currently ongoing.
The inclusion criteria were as follows:
1. Patients who had being prescribed for at least 1 year, but
<5 years, with one of the antiresorptive therapies avail-
able for the treatment of postmenopausal osteoporosis
at the time of recruitment (i.e., alendronate, risedronate,
and raloxifene).
2. Patients with a history of one or more vertebral defor-
mities (radiologically documented) and/or hip fracture at
the time of prescription. This identifies eligibility to full
reimbursement for osteoporosis treatment according to
Italian rules (Nota 79).(15)
3. Patients who did not discontinue treatment or with a
treatment compliance > 50% (i.e., the patients took
>50% of the prescribed doses; patients switching from
one to another of the three reference treatments were
also included.
4. Patients currently not treated with an investigational
drug or procedure.
The exclusion criteria were as follows:
1. Age < 21 years.
2. Patients on corticosteroid therapy for >6 months at the
time of recruitment.
Data were collected on data collection forms (DCFs) re-
porting patient demographics, medical and osteoporosis
history, risk factors for osteoporosis, medication use, dis-
ease status, and health-related quality of life (data not
shown). In 64% of the cases, the recruitment visit coincided
with the second visit at the osteoporosis out-patient clinics,
and in the remaining cases, this was the third visit. The time
lag considered for treatment duration at enrollment was
that elapsed since the first visit at the osteoporosis center.
Although not required, in 91% of the patients, a new
spine X-ray was taken at the time of recruitment. Previous
fractures after age 40 were distinguished between those oc-
curred before treatment, making the patients eligible to
“Nota 79,” and those occurred during treatment. For all
fractures, the following information was recorded: site, type
of trauma (if any), radiographic ascertainment, severity of
associated symptoms, and hospitalization. The history of
the fractures that led to the application for the “Nota 79”
was accurate for the legal requirement. Most vertebral frac-
tures in ICRs were diagnosed by the presence of severe and
long-lasting back pain, confirmed by X-rays. In ICRs, X-
rays coincided with the recruitment time (i.e., the patients
came into the center for the occurrence or worsening of
back pain and were recruited in the study). Spine X-rays
were also obtained in patients complaining of moderate
back pain, but none of them were totally asymptomatic.
The occurrence of incident vertebral fracture was not
adjudicated by any central reviewer of X-ray data. New
vertebral fractures were identified per protocol according
to the guidelines included in the “Nota 79”(15) (i.e., a de-
crease in vertebral height at any level >4 mm or >15%). It
should be pointed out that, because the time that elapsed
from the initial spine X-ray that made the patients eligible
for “Nota 79” and initiation of antiresorptive therapy
ranged from 1 to 29 months (Table 1, disease duration mi-
nus treatment duration), we cannot rule out that some pa-
tients may have been classified ICR as a consequence of a
worsening of a previous vertebral deformity rather than for
new fractures.
At enrollment, details of previous osteoporosis medica-
tions were type of treatment, switching among therapies,
level of compliance (categorized as 50–75% and >75%),
and addition of calcium and vitamin D (500–1000 mg cal-
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cium and 400–800 IU of vitamin D). This latter information
was carefully collected by a specific questionnaire. The pa-
tients who had been taking supplements of calcium and
vitamin D were further categorized for a compliance lower
or higher than 50%.
Analysis
Patients were excluded from the analysis if they did not
meet the inclusion criteria or if the DCFs did not include
data on demographics, osteoporosis treatment, and previ-
ous fractures.
All data management and analysis was centralized and
conducted according to a prespecified plan by an indepen-
dent clinical research organization (MediData, Modena,
Italy). Descriptive summary statistics such as frequencies,
percentages, means, and SDs were used to describe the
study population at baseline and for ICRs and ACRs, re-
spectively. Comparisons between the two cohorts were
made using t-tests for continuous data. Logistic regression
analysis was used to calculate the RR for ICRs. 2 tests
were used for categorical data. p values <0.003 were con-
sidered statistically significant, giving an overall significance
level of 0.10 across all tests . Analyses were carried out
using SAS software version 8.2.
RESULTS
Characteristics of the study population are reported in
Table 1. Of the original cohort of 1421 patients, 302 did not
meet the eligible criteria, and 239 patients were excluded
because important predefined data were missing. The
population analyzed in this study is made up of 880 post-
menopausal women. Twenty-five percent (n  220) were
defined as ICRs according to the definition previously re-
ported. In this subset, there were 35% of patients with a
single vertebral fracture, and 60% with more than one ver-
tebral fracture recorded as new or worsening of previous
fractures. All incident vertebral fractures should be defined
as “clinical” fractures, even though in 12 cases, the detec-
tion of a new vertebral deformity was associated with only
moderate and chronic back pain. Only 5% of ICRs pre-
sented other osteoporotic fractures (data not shown). Both
cohorts of ACRs and ICRs were comparable for age, body
mass index (BMI), and type of osteoporosis treatment.
Alendronate was the most frequently prescribed drug
(53.2%), followed by a mixture of the three (19.8%), rise-
dronate (15.8%), and raloxifene (11.2%). ICRs and ACRs
were significantly different for (1) a more severe disease at
the time of prescription of the osteoporosis treatment, with
a greater proportion of patients with more than one verte-
bral deformity; (2) osteoporosis treatment duration (2.79
versus 2.14 years; p < 0.001); (3) worse treatment compli-
ance; and (4) less frequent intake of calcium and vitamin D
supplements.
Logistic regression analysis results are reported in Table
2. When data were adjusted for the duration of treatment,
significant predictors of inadequate clinical response to
treatment included poor compliance (RR  1.68 for com-
pliance 50–75% versus >75%) and number of pretreatment
vertebral fractures (RR 6.21 for more than two prevalent









Age (years) 68 (53–79) 69 (52–79) 67 (53–79) NS
Body mass index (kg/m2) 25.2 (19.5–33.3) 25.3 (19.2–35.2) 25.1 (19.5–32.8) NS
Disease duration (years)* 2.8 (1.1–1.2) 3.8 (1.1–12.8) 2.6 (1.1–10.3) <0.001
Treatment duration (years)† 2.0 (1.0–4.5) 2.8 (1.1–4.7) 1.8 (1.0–4.4) <0.001
Prevalent fractures:
1 vertebral 366 (41.6%) 66 (30.0%) 300 (45.4%) <0.001
>1 vertebral 415 (47.1%) 121 (55.0%) 294 (44.5%) <0.001
Hip 40 (4.5%) 9 (4.1%) 31 (4.7%) <0.001
Vertebral + nonvertebral 59 (6.7%) 24 (10.9%) 35 (5.3%) <0.001
Prevalent traumatic fractures 95 (10.8%) 26 (11.8%) 69 (10.4%) NS
Treatment distribution: NS
Alendronate 468 (53.2%) 128 (58.2%) 340 (51.5%)
Risedronate 139 (15.8%) 19 (8.6%) 120 (18.2%)
Raloxifene 99 (11.2%) 17 (7.7%) 82 (12.4%)
Mixture 174 (19.8%) 56 (25.4%) 118 (17.9%)
Co-administration of calcium and vitamin D
No 332 (37.7%) 100 (45.5%) 232 (35.2%) 0.02
Yes, compliance < 50% 109 (12.4%) 22 (10.0%) 87 (13.2%)
Yes, compliance > 50% 439 (49.9%) 98 (44.5%) 341 (51.7%)
Compliance to treatment:
50–75% 55 (6.2%) 21 (9.5%) 34 (5.1%) 0.004
>75% 748 (85.0%) 174 (79.1%) 574 (87.0%)
Not determined 77 (8.7%) 25 (11.4%) 52 (7.9%)
Values are expressed as median (95% CI) or absolute numbers (%).
* Time elapsed since the first diagnosis of established osteoporosis.
† Time on treatment with antiresorptive drugs of “Nota 79.”
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vertebral fractures; RR 2.00 for more than one prevalent
vertebral fracture). In patients taking no calcium and vita-
min D supplements, the risk of ICR was increased by 98%
versus patients taking the supplements with good (>50%)
compliance (p < 0.001) and by a nonsignificant 14% versus
patients taking supplements with low (<50%) compliance
(Table 2).
More patients in the ICR group switched treatment
(Table1). Actually, the occurrence of a fracture while on
treatment was the cause for changing treatment in one
fourth of the cases, but it never led to discontinuation of any
antiresorptive therapy. Treatment type was not associated
with differences in the risk o5f inadequate response when
the data were adjusted for the duration of treatment and
the baseline severity of the disease.
The distribution of ICRs according to the compliance
level to antiresorptives and the intake of calcium + vitamin
D supplements (compliance > 50%) is shown in Fig. 1. The
proportion of patients taking calcium and vitamin D
supplements with adequate compliance were significantly
higher (p < 0.05) among compliants (>75%) to antiresorp-
tive (50.9%) than among poor compliants to antiresorbers
(34.5%; data not shown). Poor compliance and no intake of
calcium and vitamin D supplements were the major deter-
minants of inadequate clinical response to treatment. Fig-
ure 2 shows the proportion of ICRs when both parameters
were considered in their different combinations. From this
analysis, the proportion of ICRs was 36.5% among patients
with poor compliance and not taking supplements and
20.7% in patients both compliant and taking supplements
regularly (>50%).
DISCUSSION
Osteoporotic fracture is one of the most important public
health concerns among the elderly. Available therapies
have shown to significantly decrease the risk of fracture and
its related morbidity, particularly in women with postmeno-
pausal osteoporosis,(3) but at present, no osteoporosis drug
therapy completely abolishes this risk. Both incidence and
underlying causes of this inadequate clinical response have
not been properly studied.
Here we report the prevalence of fragility fractures in
patients prescribed for at least 1 year with alendronate,
risedronate, and raloxifene. The proportion of inadequate
clinical responders was 25% over an average period of treat-
ment of 2.3 ± 1.15 years. This proportion is considerably
greater than that observed in the active arm of any pre-
vious RCT for antiresorptives agents, where patients not
responding to treatment ranged from 2.1% to 18.1% over
3 years.(4–10,14) There are several explanations for the signifi-
cant number of ICRs reported in our study. First of all, in this
study, only patients with a compliance >50% and those who
did not discontinue therapy were enrolled; therefore, our
setting is closer to a “per-protocol” than to an “intention to
treat” analysis, as reported in RCTs. Because immediate pre-
treatment X-rays were not available for all patients, an un-
identified number of ICRs had possibly worsened from pre-
vious deformities rather than being new vertebral fractures.
Furthermore, our study population was made up of patients
registered for osteoporosis treatment reimbursement ac-
cording to “Nota 79,” which requires the presence of at
least one atraumatic severe vertebral or hip fracture. Our
cohort was somewhat age matched with patients enrolled
in the major RCTs performed using antiresorptives; how-
ever, osteoporosis was significantly more severe in our pa-
tients compared with the RCT population.(4–7,14) This could
be responsible for the switching through different anti-
resorptives in a large proportion of the ICRs. Unlike
RCTS, the average compliance in routine setting is con-
siderably poorer, when different compliance levels are
considered. In RCTs, the investigators tend to exclude pa-
tients with co-morbidity or with numerous associated thera-
pies to limit the number of trial withdrawals. In our study,
TABLE 2. LOGISTIC REGRESSION ANALYSIS FOR RELATIVE RISK
OF INADEQUATE CLINICAL RESPONSE TO TREATMENT
RR 95% CI
Treatment duration (1 year) 1.68 1.46–1.93
Compliance (50–75% vs. >75%) 1.66 1.08–2.54
Supplements of calcium + vitamin D
(NO vs. YES compliance > 50%) 1.98 1.38–2.83
(NO vs. YES compliance < 50%) 1.14 0.68–1.91
Prevalent vertebral fracture (>2 vs. 1) 6.21 3.09–12.5
Prevalent vertebral fractures (>1 vs. 1) 2.00 1.69–2.77
The model include only the variable that remained significant after ad-
justment for the duration of treatment.
FIG. 1. Proportion of ICRs in relationship with the co-
administration of calcium and vitamin D supplements to antire-
sorptive therapy (compliance level > 50%) and to a compliance to
antiresorbers of 50–75% and >75%.
FIG. 2. Incidence of inadequate clinical response in patients
with all possible combinations of treatment compliance and intake
of calcium and vitamin D supplements > 50% compared with no
or inadequate supplementation.
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65% of the patients were taking one or more other phar-
macological therapies and had several other diseases such
as respiratory, heart, liver, and renal conditions (data not
shown), all potentially related to an increased risk of frac-
ture. An obvious limitation of the retrospective design of
the study is the inclusion only of patients who did return for
a follow-up visit. The direction of the bias (if any) associ-
ated with this patient selection remains uncertain.
For the first time in our study, we were able to investigate
the conditions associated with an inadequate clinical re-
sponse. The ICRs had a more severe form of osteoporosis,
as documented by the number of fractures that led to os-
teoporosis treatment. The risk of inadequate response was
6.2-fold higher in patients with three or more prevalent
vertebral fractures than in patients with one vertebral de-
formity. This finding was expected, and it has been consis-
tently reported also during pivotal RCTs. In the FIT trial
with alendronate, the proportion of patients who sustained
a vertebral fracture in the active arm was 5.2% in patients
with one prevalent vertebral fracture and 12.8% and 16.3%
in women with two or three to four prevalent vertebral
deformities, respectively.(16) In the MORE study, patients
with prevalent severe vertebral deformities sustained more
frequently new vertebral fractures in both placebo and ac-
tive arms than patients with prevalent mild deformities.(17)
Furthermore, we were able to measure the impact of
compliance and calcium and vitamin D supplements to in-
adequate clinical response to treatment.
The importance of treatment compliance has been ad-
dressed by other studies. Rates of noncompliance with os-
teoporosis therapy were found as high as 50% among
women with osteoporosis, limiting the effectiveness of
treatment.(18,19) In a study of 11,248 women with osteopo-
rosis in clinical practice, 51% were poorly compliant with
osteoporosis medication, and these patients had a 16%
greater risk of fracture than patients who were compliant
with therapy.(20) In all these studies, the range of compli-
ance was wider, including also patients who discontinued
treatment. In our study, we observed that even lowering
compliance from 75% to 50–75% increased the risk of in-
adequate clinical response by 66%.
In all pivotal RCTs, randomized patients were vitamin D
repleted, and calcium and vitamin D supplements were
given to both placebo and active arms. The antifracture
efficacy of the tested drugs cannot be guaranteed in differ-
ent settings. From a survey done in most of the centers
participating in our study, 25-hydroxyvitamin D levels were
seldom measured (data not shown), despite that vitamin D
deficiency is extremely frequent in all Italian regions.(21,22)
It is likely that a large proportion of the patients included in
this study were somewhat vitamin D deficient at the time of
treatment initiation. Calcium and vitamin D supplements
were taken by only one half of the patients. We observed
that, in those who took the supplements correctly, the rate
of inadequate clinical response to treatment decreased by
98% versus those who did not take any supplement. This
seems to explain a large proportion of ICRs observed in this
study compared with those reported in the active arms of
RCTs with alendronate, risedronate, and raloxifene.
In conclusion, in our study, we, for the first time, assessed
the incidence of new fractures in patients prescribed anti-
resorptive agents for at least 1 year. The incidence of ICR
was ∼8.9% per year, considerably higher than that observed
in the active arm of all previous pivotal RCTs. This was
likely explained by the higher disease severity and the more
frequent co-morbidity reported in this cohort of patients.
Our results emphasize the importance of full compliance to
treatment and of adequate supplementation of calcium and
vitamin D that, together, may double the risk of inadequate
clinical response to osteoporosis treatment.
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Carlina Albanese, MD, Policlinico Universitario Umberto I,
Roma; Marco Antonelli, MD, Ospedale San Camillo Forlanini,
Roma; Annamaria Aversa, MD, Ospedale S.Carlo Borromeo, Mi-
lano; Cataldo Bancheri, MD, Ospedale Sandro Pertini, Roma;
Mario Barbagallo, MD, Policlinico Universitario, Palermo; Al-
fredo Bardoscia, Fondazione Maugeri, Cassano Murge (BA); Pi-
etro Bertoni, MD, Policlinico San Marco, Mestre (VE); Gerolamo
Bianchi, MD, Ospedale La Colletta, Arenzano (GE); Mario
Biondi, MD, Ospedale Morgagni Pierantoni, Forlì; Maria Luisa
Brandi, MD, Policlinico Universitario Careggi, Firenze; Michele
Calitro, MD, Ospedale Civile Caduti in Guerra, Canosa (BA);
Rosario Cangelosi, MD, Ospedale San Biagio, Marsala (TP);
Francesco Paolo Cantatore, MD, Ospedale Riuniti, Foggia; Giu-
liano Cenci, MD, Ospedale Santa Croce, Fano (Pesaro Urbino);
Antonio Cianci, MD, Ospedale Ferrarotto S. Bambino, Catania;
Giovanni Coppi, MD, Ospedale San Camillo Forlanini, Roma;
Luca Dalle Carbonare, MD, Policlinico Universitario, Padova;
Massimo D’Amore, MD, DIMIMP Università degli studi di Bari,
Bari; Giovanni D’Avola, MD, Servizio Reumatologia ed Osteo-
porosi AUSL 3, Catania; Roberto De Candia, MD, Ospedale Civ-
ile San Bortolo, Vicenza; Antonio Del Puente, MD, Policlinico
Universitario “Federico II”, Napoli; Pier Giorgio Delvino, MD,
Ospedale Sant’Andrea, Vercelli; Alessandro Di Felice, MD, Os-
pedale Civile Renzetti, Lanciano (CH); Paolo Filipponi, MD, Os-
pedale Civile, Umbertide (PG); Carmelo Erio Fiore, MD, Osped-
ale Garibaldi, Catania; Cristiano Maria Francucci, MD, Ospedale
Umberto I, Ancona; Bruno Frediani, MD, Policlinico Universi-
tario “Le Scotte”, Siena; Nicola Frisina, MD, Policlinico Univer-
sitario, Messina; Beatrice Fruttero, MD, Ospedale SS Annun-
ziata, Savigliano (CN); Raffaele Ghirardi, MD, Ospedale C.
Poma, Pieve di Coriano (MN); Diego Giuntini, MD, Ospedale
Riuniti, Trieste; Andrea Giustina, MD, Spedali Civili, Brescia;
Giovanni Lentini, MD, Ospedale Buccheri La Ferla, Palermo;
Vincenzo Lo Cascio, MD, Policlinico Universitario “G.B. Rossi”,
Verona; Vittorio Lucchese, MD, Ospedale Estense, Modena; Au-
gusto Manzara, MD, Ospedale Villa Scassi, Genova; Antonia
Matina, MD, Policlinico Universitario, Palermo; Domenico
Maugeri, MD, Ospedale Cannizzaro, Catania; Quirico Mela, MD,
Policlinico Universitario, Monserrato (CA); Alfredo Nardi, MD,
Ospedale S. Maria della Misericordia, Rovigo; Rita Occhipinti,
MD, Ospedale Civile, Belluno; Giangiacomo Osella, MD, Osped-
ale S.Luigi Gonzaga, Orbassano (TO); Giuseppe Perpignano,
MD, Policlinico Universitario, Monserrato (CA); Eustacchio Pi-
sciotta, MD, Ospedale Civile Tinchi, Pisticci (MT); Giuseppe
Quattrocchi, MD, Centro Riabilitazione Mandalari, Messina;
Giovambattista Rini, MD, Policlinico Universitario, Palermo;
Maurizio Rossini, MD, Policlinico Universitario, Verona; Stefano
Savoca, MD, Ospedale Ascoli Tomaselli, Catania; Ferdinando
Silveri, MD, Università Politecnica delle Marche, Jesi (AN);
Giuseppe Termini, MD, Policlinico Universitario, Palermo.
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